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Background: Although compelling evidence has shown that obsessive-compulsive disorder
(OCD) has a strong genetic component, its genetic basis remains to be elucidated. Identifying
biological abnormalities in non-affected relatives is one of the strategies advocated to isolate
genetic vulnerability factors in complex disorders. Because peripheral serotonergic disturbances
are frequently observed in OCD patients, the aim of this study was to investigate if they could
represent endophenotypes, by searching for similar abnormalities in the unaffected parents of
OCD patients.
Methods: We assessed whole blood serotonin (5-HT) concentration, platelet 5-HT transporter
(5-HTT) and 5-HT2A receptor binding characteristics, and platelet inositol trisphosphate (IP3)
content in a sample of OCD probands (n = 48) and their unaffected parents (n = 65), and
compared them with sex- and age-matched controls (n = 113).
Results: Lower whole blood 5-HT concentration, fewer platelet 5-HTT binding sites, and higher
platelet IP3 content were found in OCD probands and their unaffected parents compared to
controls. Whole blood 5-HT concentration showed a strong correlation within families (p<0.001).
The only parameter that appeared to discriminate affected and unaffected subjects was 5-HT2A
receptor binding characteristics, with increased receptor number and affinity in parents and no
change in OCD probands.
Conclusions: The presence of peripheral serotonergic abnormalities in OCD patients and their
unaffected parents supports a familial origin of these disturbances. These alterations may serve
as endophenotypic markers in OCD, and could contribute to the study of the biological
mechanisms and genetic underpinnings of the disorder.
Key Words: serotonin, serotonin transporter, 5-HT2A receptor, binding, inositol triphosphate,
intrafamilial correlation
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Introduction
Obsessive-compulsive disorder (OCD) is a severe, chronic neuropsychiatric illness,
characterized by recurrent, distressing, unwanted thoughts (obsessions) and repetitive,
ritualistic behaviors (compulsions). OCD is a common disorder, affecting between 2% and 3%
of the population (Weissman et al. 1994). Although the precise etiology of the disorder remains
unknown, the results of twin studies (Jonnal et al. 2000), family genetic studies (Nestadt et al.
2000b; Pauls et al. 1995), and segregation analyses (Alsobrook et al. 1999; Nestadt et al.
2000a), have provided compelling evidence that OCD has a strong genetic component.
However, like other major psychiatric disorders, OCD fails to follow Mendelian patterns of
inheritance and is considered as a complex genetic disorder.
The first genome-scan for OCD performed in a small number of families found suggestive
evidence for linkage to chromosome 9p24 (Hanna et al. 2002) and this finding was recently
replicated in an independent dataset (Willour et al. 2004). In addition, several theoretically
relevant functional candidate genes have been examined in OCD, but no susceptibility genes
have yet been identified with certainty. The difficulty in identifying the responsible genes may be
the consequence of the clinical and genetic heterogeneity of the disorder. The endophenotype
approach is one of the strategies advocated to identify relevant phenotypes in complex
disorders (Leboyer et al. 1998). Endophenotypes are variables that correlate with a given
disease, are usually subclinical, involve fewer genes than those involved in the disease
syndrome itself, and may thus serve to better define the disorder and could assist in the
identification of genes conferring vulnerability to the disorder (Gottesman and Gould 2003). To
meet the criteria for an endophenotype, a marker must be present in affected individuals, it
should be heritable and co-segregate with the illness, it should be state-independent (i.e.,
manifests in an individual whether or not the illness is active), and must be found among
unaffected relatives of patients at a higher rate than in the general population (Leboyer et al.
2003; Gottesman and Gould 2003).
The selective response to drugs that potently inhibit the reuptake of serotonin (5-
hydroxytryptamine, 5-HT) has been amply demonstrated in OCD and was at the origin of the 5-
HT hypothesis concerning the pathophysiology of the disorder (Barr et al. 1992). The 5-HT
transporter (5-HTT) is a critical component of the serotonergic system and the principal site of
action of the widely prescribed 5-HT reuptake inhibitors (Blier and de Montigny 1999).
Untreated OCD patients exhibit either reduced (Yaryura-Tobias et al. 1979) or normal (Cath et
al. 2001; Delorme et al. 2004; Flament et al. 1987; Hanna et al. 1991; Insel and Winslow 1992)
whole blood or platelet 5-HT levels, whereas the binding capacity (Bmax) of the platelet 5-HTT
is consistently reduced, both for [3H]-paroxetine (Marazziti et al. 1999; Sallee et al. 1996) and
[3H]-imipramine (Bastani et al. 1991; Marazziti et al. 1992; Marazziti et al. 1997; Weizman et al.
1992). Treatment with 5-HT reuptake inhibitors lowers whole blood 5-HT concentration and
further decreases the number of 5-HTT binding sites, and the magnitude of the decrease is
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correlated with clinical improvement (Black et al. 1990; Delorme et al. 2004; Flament et al.
1987; Hanna et al. 1993).
The platelet 5-HT2A receptor binding characteristics and inositol 1,4,5 triphosphate (IP3)
content may also be relevant as markers of vulnerability in OCD. Pharmacological studies
suggest the implication of 5-HT2A receptors in the pathophysiology of OCD, since risperidone, a
5-HT2/D2 receptor antagonist, appears to potentiate the efficiency of 5-HT reuptake inhibitors in
resistant OCD patients through an effect mediated by 5-HT2A receptors (Marek et al. 2003;
McDougle et al. 2000). Furthermore, we recently reported elevated platelet IP3 content without
modification of the Bmax or the Kd of the platelet 5-HT2A receptor in drug-free OCD patients,
suggesting an increase in the intrinsic activity of 5-HT2A receptors resulting in overstimulation of
the platelet phosphoinositide signaling system (Delorme et al. 2004).
The aims of this study were to confirm the presence of peripheral serotonergic disturbances
in a sample of OCD probands and to search for the presence of similar abnormalities in their
unaffected parents. The parameters investigated were whole blood 5-HT content, platelet 5-
HTT and 5-HT2A receptor binding characteristics, and platelet IP3 content. Such serotonergic
disturbances observed in OCD probands and their unaffected relatives would suggest that they
might be endophenotypic markers of the vulnerability to OCD, and could be used as alternative
biological phenotypes in genetic studies.
Patients and Methods
Subjects
Forty eight probands suffering from OCD according to DSM-IV criteria were recruited from two
university hospital psychiatric departments for children (Hôpital Robert Debré, Paris) and
adults (Hôpital Albert Chenevier, Créteil). The clinical and demographic characteristics of OCD
probands are shown in Table 1. Lifetime psychiatric history was evaluated during a direct
interview, either with the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger et al.
1994) for patients over the age of 17 years, or with the Kiddie Schedule for Affective Disorders
and Schizophrenia - Epidemiologic version (K-SADS-e) (Orvaschel et al. 1982) for those aged
under 17 years. The symptom checklist and ordinal scales of the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS, Goodman et al. 1989) were used to evaluate the severity and the
diversity of OC symptoms at the time of inclusion (Table 1). To be included in the study,
patients had to have OCD as their main disorder and no associated depression at the time of
inclusion. However, some patients had lifetime comorbid disorders, including anxious disorders
(n=19), Tourette’s syndrome (n=17), attention deficit hyperactivity disorder (n=15), eating
disorders (n=3), and alcohol dependence (n=1). Fifteen patients were receiving 5-HT reuptake
inhibitors at the time of assessment, while the remaining 33 patients received no medication at
the time of assessment and had been drug-free for at least eight weeks. Drug treatment was
limited to a monotherapy and had been introduced for more than twelve weeks at the time of
blood sampling. The choice of 5-HT reuptake inhibitors and the dose were left to the clinician.
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Among the 15 treated subjects included, eight were treated with sertraline (106.3 ± 49.7
mg/day), three with paroxetine (26.7 ± 11.7 mg/day), two with fluoxetine (100 mg/day) and two
with fluvoxamine (35 ± 7.07 mg/day).
In addition, 65 parents of OCD probands were also included in the study (Table 1). All
parents were directly interviewed with the DIGS. Parents found to have a lifetime history of
OCD, a mood disorder at the time of the interview, or who had taken a psychotropic treatment
during the past eight weeks, were excluded from the study.
Controls (n=113), sex- and age-matched with probands and relatives, were healthy
volunteers recruited among blood donors and orthopedic patients at the Lariboisière Hospital in
Paris. Control subjects were receiving no psychotropic treatment at the time of assessment
and had been drug-free for at least eight weeks. All patients, parents, and controls were
Caucasian. The local Research Ethics Board approved the study protocol. Written informed
consent was obtained from all participating subjects. If the proband was under 18 years old,
the proband's consent and written parental consent were obtained.
Blood sampling
All participants were asked to follow a diet poor in tryptophan and 5-HT during two days before
the blood sampling. Blood samples (7-10 ml) were collected into tubes containing EDTA
between 8-10 a.m. One milliliter of blood was immediately stored at –80°C until used for the 5-
HT assay. Platelet-rich plasma (PRP) was prepared from the rest of the sample within two
hours by centrifugation at 200 g for 15 min at room temperature. The PRP was collected and
centrifuged at 2000 g (4°C, 15 min). Platelet pellets were stored at –80°C until used.
Biochemical measurements
Serotonin. Whole-blood 5-HT concentration was determined by a radioenzymatic procedure as
previously described (Matuchansky and Launay 1995).
Binding of [3H]-imipramine, [3H]-paroxetine, and [125I]-LSD. Platelet membranes were prepared
by lysing each platelet pellet hypotonically in 5 ml of 5 mM Tris-HCl, 5 mM EDTA (pH 7.4). The
samples were homogenized with a polytron and centrifuged twice at 20,000 g, 4°C, for 30 min.
The supernatant was discarded and the pellet was suspended in incubation buffer (50 mM
Tris-HCl, 3 mM KCl, 120 mM NaCl, pH 7.4) to a concentration of 0.5–1.5 mg protein/ml.
Membranes (100 µl of the platelet membrane suspension) were incubated for 90 min at 4°C in
300 µl of incubation buffer with [3H]-imipramine (specific activity 49.3 Ci/mmol, NEN), [3H]-
paroxetine (specific activity 28.5 Ci/mmol, NEN), or [125I]-lysergic acid diethylamide (LSD)
(specific activity 2200 Ci/mmol, NEN) at various concentrations (0.1, 0.3, 0.6, 1.25, 2.5, 5, and
10 nM). Non-specific binding was determined by replacing 100 µl of buffer with 100 µl of
desipramine (100 µM), fluoxetine (10 µM), or ketanserin (1 µM). After incubation (90 min at
4°C for [3H]-imipramine, 2 h at 20°C for [3H]-paroxetine, 2 h at 37°C for [125I]-LSD), the
contents of each tube were diluted in 5 ml of incubation buffer at 0°C and immediately filtered
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through Whatman GF/B glass fiber filters. The filters were washed three times with 5 ml of
incubation buffer and dried. Radioactivity was measured by liquid (tritiated ligands) or solid
([125I]-LSD) scintillation spectrometry. Specific binding was defined as the difference between
total and non-specific binding. The binding data were analyzed with the iterative non-linear
least-squares curve-fitting program, EBDA-ligand, and values for Bmax and Kd were
determined.
Inositol triphosphate. The platelet concentration of IP3 was measured radioimmunologically as
described previously (Delorme et al. 2004).
Genotyping
Two polymorphisms in untranslated regions of the 5-HTT gene (SLC6A4) were investigated to
explore the possible molecular mechanisms underlying serotonergic endophenotypes: a
variable number of tandem repeats (VNTR) in intron 2, and an insertion/deletion in the
promoter region (5-HTTLPR). The polymerase chain reaction (PCR) was performed with
primers flanking the polymorphisms in the promoter and in intron 2 following protocols already
published (Betancur et al. 2002).
Statistical analysis
Because the observed distribution of several biochemical parameters was not normal in the
different groups (OCD probands, unaffected relatives, and controls), inter-group comparisons
were made with a nonparametric test, the Mann-Whitney U test. The relationship between
biochemical parameters and genotypes was analyzed with non parametric analysis of variance,
using the Kruskall-Wallis test. To study intrafamilial correlations, we used the Fisher intraclass
correlation method with the biochemical parameters as continuous variables. This method
involves the analysis of variance “within families” (s2w) and “between families” (s2b). The
intraclass coefficient (ICC) is then calculated as:
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with “a” being the total number of families, and “ni” being the number of subjects in the families.
If there is no aggregation of the trait within families, and if the trait is randomly distributed, then
ICC = 0. If the trait is distributed only within families, then the ICC is significantly different from
0. All statistical analyses were performed with the aid of SPSS/PC+ computer software.
Results
Traits present in affected individuals
To test if the peripheral serotonergic parameters studied were associated with the illness, the
proband group and their respective sex- and age-matched controls were compared. As shown
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in Figure 1, OCD probands had lower whole blood 5-HT concentration (p<0.001), reduced
number of platelet 5-HTT binding sites ([3H]-imipramine Bmax, p<0.05; [3H]-paroxetine Bmax,
p<0.001), lower 5-HTT binding affinity ([3H]-paroxetine Kd, p<0.001), and higher platelet IP3
content (p<0.001) than controls (Figure 1). None of the other peripheral serotonergic
parameters differed between OCD patients and controls. Similar results were obtained in the
subgroup of drug-free OCD probands (n = 33) when compared to their respective sex- and
age-matched controls: lower whole blood 5-HT level (p<0.05), reduced number of platelet 5-
HTT binding sites ([3H]-paroxetine Bmax, p<0.001), reduced 5-HTT binding affinity ([3H]-
imipramine Kd, p<0.05; [3H]-paroxetine Kd, p<0.05), and higher platelet IP3 content (p<0.001)
(Figure 1). In the subgroup of probands treated with 5-HT reuptake inhibitors (n = 15), we also
observed analogous abnormalities of the peripheral serotonergic parameters (Figure 1).
Although the dose, type and efficacy of 5-HT reuptake inhibitors were not controlled in the
subgroup of treated probands, these findings suggest that the observed biochemical
abnormalities represent a trait, not influenced by illness state. Furthermore, no significant
gender differences were found for any of the serotonergic parameters when comparing male
and female OCD patients.
Traits present in unaffected relatives
To test if the peripheral serotonergic abnormalities observed in OCD probands were also
present in the unaffected parents, they were compared to their respective sex- and age-
matched controls. The decrease in blood 5-HT content (p<0.001), and in the number of 5-HTT
binding sites ([3H]-imipramine Bmax, p<0.001; [3H]-paroxetine Bmax, p<0.001), the lower 5-
HTT binding affinity ([3H]-imipramine Kd, p<0.001), and the increase in platelet IP3 content
(p<0.05) were also found in unaffected parents of OCD patients (Figure 1). In addition, 5-HT2A
receptor binding characteristics differed in relatives and controls, with an increase in [125I]-LSD
Bmax (p<0.001) and an increased affinity (p<0.001) in the group of parents (Figure 1).
Familial aggregation of the traits
To test if the peripheral serotonergic abnormalities observed in OCD probands and their
parents were aggregated in OCD families, the intrafamilial correlation was calculated in the
subgroup of unaffected relatives who had a proband in the sample (n = 59). Only whole blood
5-HT concentration appeared aggregated within families (ICC = 0.45, p<0.001). The
intrafamilial correlation remained significant when examined in the subgroups composed of
probands and their fathers (n = 24, ICC = 0.37, p<0.02) or probands and their mothers (n = 35,
ICC = 0.53, p<0.001). No significant intrafamilial correlation was observed for any of the other
biochemical parameters.
Relationship between platelet serotonergic markers and polymorphisms in the 5-HTT gene
To test if two polymorphisms in the 5-HTT gene, a VNTR in intron 2 and 5-HTTLPR in the
promoter region, could play a role in the peripheral serotonergic abnormalities observed in
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OCD probands and their unaffected parents, we studied the relationship between genotypes
and biochemical variables. We did not observe any effect of the genotypes on whole blood 5-
HT level, Kd or Bmax of 5-HTT measured with [3H]-paroxetine and [3H]-imipramine (Table 2).
Discussion
Abnormalities in peripheral serotonergic parameters were tested as putative trait markers for
OCD by assessing a sample of OCD patients and their unaffected parents. Our results
showing lower whole blood 5-HT concentration, fewer platelet number of 5-HTT, and higher
platelet IP3 content in patients with OCD compared to controls had already been described
previously by our group and others. In contrast, this is the first report to our knowledge to
describe the same abnormalities in unaffected parents of OCD patients.
As OCD displays a complex pattern of inheritance (Nestadt et al. 2000a), these abnormalities
of peripheral serotonergic parameters could represent the genetic liability of unaffected relatives
of probands for the disorder. The highly significant intrafamilial correlation observed for whole
blood 5-HT concentration suggests that the heritability of this marker is high. This is in
agreement with a previous study, showing that whole blood 5-HT level had a heritability of 0.99
in a founder population (Ober et al. 2001). Thus, blood 5-HT level could be a heritable
component in OCD families, and could be used as an alternative phenotype for OCD. Use of
quantitative traits as an alternative phenotype is recognized to be of critical importance for
understanding the genetic basis of complex diseases, and has been useful in facilitating gene
identification in non-psychiatric disorders. For example, the QT elongation on electrocardiogram
was used to discover the genes underlying the long QT syndrome, characterized by syncope,
ventricle arrhythmias, and sudden death (Keating et al. 2001). In the field of psychiatry,
disturbances of P50 auditory evoked response and smooth pursuit eye movements are among
the best established endophenotypes present in schizophrenic patients and their unaffected
relatives, and linkage studies have already identified the loci involved in chromosome 15q
(Freedman et al. 1997) and 6p (Arolt et al. 1996), respectively. In OCD, stratification by 5-HT
level could decrease genetic heterogeneity and increase power to identify susceptibility genes
in association and linkage studies.
The reduction in whole blood 5-HT level in OCD patients had been described previously
(Yaryura-Tobias et al. 1979), although other studies, including our own, reported that the
baseline concentrations of 5-HT do not differ from those in controls (Cath et al. 2001; Delorme
et al. 2004; Flament et al. 1987; Hanna et al. 1991; Insel and Winslow 1992). These
discrepancies may be due to the small number of patients studied previously, the seasonal
effects on 5-HT level (Brewerton et al. 1993), as well as the effects of sex, age, and ethnic
origin on 5-HT levels in the absence of matched controls. Furthermore, the diet poor in
tryptophan and 5-HT followed by all our subjects before blood sampling may have revealed the
reduction in 5-HT levels in OCD patients, whereas the majority of previous studies apparently
were not controlled for diet. Finally, the marked heterogeneity of whole blood 5-HT
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concentration in OCD patients raises the possibility that decreased 5-HT levels are present only
in a subgroup of patients. In our sample, the distribution of whole blood 5-HT in un-medicated
probands appears to be non-normally distributed, with two different subgroups: one (n=10) with
a high level of whole blood 5-HT (0.85 ± 0.07 in OCD vs. 0.49 ± 0.23 in their 10 respective
controls, Mann-Whitney U test, Z = -3.02, p=0.02) and another (n=23) with hyposerotonemia
(0.22 ± 0.16 in OCD vs. 0.55 ± 0.18 in their 23 respective controls, Mann-Whitney U test, Z = -
4.9, p=0.0001). Although these findings should be interpreted with caution given the limited
sample size, they are in agreement with previous findings in the literature showing altered 5-HT
levels only in a specific subgroup of patients. For instance, Cath et al. (2001) showed that whole
blood 5-HT content was reduced only in the subgroup of OCD patients with tics. Similarly,
Hanna et al. (1995) reported lower blood 5-HT concentrations in OCD patients with a concurrent
diagnostic of disruptive behavior disorder. In our dataset, the 5-HT level was not influenced by
the presence or absence of tics, and there were no probands with disruptive behavior disorder.
As expected, the reduction in the number of 5-HTT binding sites in OCD patients described
in previous works (Bastani et al. 1991; Delorme et al. 2004; Marazziti et al. 1992, 1997, 1999;
Sallee et al. 1996; Weizman et al. 1992), was confirmed in our study. This appears to be the
most consistent abnormality of the peripheral serotonergic system observed to date in OCD. We
also observed an increase in 5-HTT binding affinity in OCD probands (decreased [3H]-
paroxetine Kd) and their unaffected relatives (decreased [3H]-imipramine Kd) when compared to
controls. Although these differences were statistically significant, their magnitude was quite
small. Nevertheless, they could be helpful in the eventual elucidation of the biology of
serotonergic endophenotypes and their relationship to genetics.
The elevated platelet IP3 content with unchanged 5-HT2A binding described as a preliminary
finding in OCD probands (Delorme et al. 2004) was confirmed in this study in a larger sample.
We previously suggested an increase in the intrinsic activity of the 5-HT2A receptor in untreated
patients to explain the increase in IP3 concentration in the absence of an increase in 5-HT2A
receptor number and affinity measured with [125I]-LSD (Delorme et al. 2004). In contrast,
unaffected relatives exhibited decreased Kd and increased Bmax of 5-HT2A receptors,
associated with an increase in IP3 content. These results suggest that the increased activity of
5-HT2A receptors could be a physiological compensatory mechanism to the very low amount of
5-HT available for binding to its targets (Blier and de Montigny, 1999). This alteration of 5-HT2A
binding characteristics represents the main biochemical difference between OCD probands and
their unaffected relatives among the serotonergic parameters studied, raising the possibility that
5-HT2A receptor regulation could be determinant in the emergence of the OCD phenotype in
genetically vulnerable individuals.
Possible molecular mechanisms underlying serotonergic endophenotypes
The molecular mechanisms involved in the alteration of the serotonergic parameters in OCD
patients and their parents remain to be elucidated. We did not observe an association between
whole blood 5-HT level, Kd or Bmax of 5-HTT (measured with [3H]-paroxetine and [3H]-
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imipramine) and two polymorphisms in the 5-HTT gene, a 5-HTTLPR in the promoter region
and a VNTR in intron 2, which act in vitro as transcriptional regulators (Lesch et al. 1996;
MacKenzie and Quinn 1999). The lack of association between 5-HT levels and 5-HTT
polymorphisms is in accordance with previous reports in individuals suffering from autism
(Betancur et al. 2002), alcoholism (Stoltenberg et al. 2002), or in healthy subjects (Greenberg et
al. 1998). However, the possibility that other polymorphisms within regulatory or coding
sequences at the 5-HTT locus could be more directly linked to the low blood 5-HT level
observed in OCD patients cannot be excluded. Recently, a rare mutation in the 5-HTT gene
coding region, Ile425Val, was reported in two unrelated families with OCD (Ozaki et al. 2003).
However, analysis of the mutant transporter in heterologous cells revealed a two-fold increase
in uptake activity (Kilic et al. 2003), which would result in increased platelet 5-HT level.
Alternatively, alterations in post-translational processing of 5-HTT protein could be
responsible for the observed effects. In particular, phosphorylation by protein-kinase C
profoundly affects 5-HTT function by inducing 5-HTT internalization (Ramamoorthy and Blakely
1999). Increased phosphorylation could directly decrease the number of active 5-HTT
molecules at the cell surface, and could account for the reduced number of platelet 5-HTT
binding sites and the low whole blood 5-HT concentration found in OCD probands and in their
unaffected parents in this study. Interestingly, an increase in platelet protein-kinase C activity
has been reported in drug-free OCD patients (Marazziti et al. 2000), supporting this hypothesis.
It is also possible that other genes might be involved in the regulation of 5-HT levels. A
recent genome-wide association study in a founder population suggested that the β3 integrin
gene on 17q21 could be an important quantitative trait locus for whole blood 5-HT (Weiss et al.
2004).
Finally, we did not observe an association between a polymorphism in the 5-HT2A receptor
gene promoter (1438G/A) and 5-HT2A receptor binding characteristics or IP3 levels in patients
with OCD or their unaffected parents (data not shown). Although endophenotypes would ideally
involve single genes, the possibility that they have a polygenic basis cannot be discarded at
present. In addition, the origin of these alterations may be epigenetic or multifactorial.
Diagnostic and familial specificity
The decrease in whole blood 5-HT and 5-HTT binding are not unique to persons with OCD or at
risk for developing such disorder, since these disturbances have also been observed in patients
with affective disorders (Cleare 1997; Alvarez et al. 1999) and in their unaffected relatives
(Leboyer et al. 1999). Moreover, increased IP3 concentration has been reported in patients with
unipolar depression (Alvarez et al. 1999). The lack of diagnostic and familial specificity of these
findings could be interpreted as an indication of shared genetic factors in OCD and affective
disorders. Recently, Nestadt et al. (2003) reinforced the hypothesis of a shared etiopathogenic
background by using latent class analysis to identify OCD-related subgroups based on
comorbidity. They observed that patients with OCD and major depressive disorder appear to
constitute a well-defined subgroup. Thus, the decreased whole blood 5-HT level and 5-HTT
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function associated with the increased IP3 level could add a nonspecific disturbance to the more
specific genetic and nongenetic causes of both disorders, thereby increasing the disease risk in
the sense of a threshold model. Alternatively, it could suggest that there are specific
interactions of the putative genes involved in these disturbances with other causal genes
resulting in the emergence of subtypes of OCD and affective disorders.
Limitations
Several limitations of this study should be noted. First, a general problem for the interpretation
of differences in affected subjects is the fact that medication may interfere with the outcome.
Here we showed that all the alterations of the serotonergic system observed in OCD probands
were also present in the subgroup of drug-free patients. The specificity of these findings is
further supported by the presence of a similar serotonergic dysfunction in the unaffected
parents of OCD patients. Therefore, our results suggest that lower whole blood 5-HT
concentration, fewer platelet number of 5-HTT, and higher platelet IP3 content may be state as
well as trait markers. Second, although there is a remarkable stability of whole blood 5-HT level
over time in normoserotonergic adult controls (Yuwiler et al. 1970), the long-term alteration of
peripheral serotonergic markers in OCD probands and their relatives remains to be proved.
Finally, except for whole blood 5-HT concentration, none of the other serotonergic parameters
showed a positive intrafamilial correlation. The lack of familial correlation for peripheral markers
that were similarly altered in OCD patients and their parents (decreased number of 5-HTT
binding sites labeled with [3H]-paroxetine and [3H]-imipramine, and increased platelet IP3
content) suggests their inheritance may be complex, with incomplete penetrance and/or
influenced by environmental factors. It is also possible that the failure to find positive
intrafamilial correlations is due to the limited sample size and that much larger study groups are
needed. Whole blood 5-HT concentration depends mainly on the activity of 5-HTT and 5-HT2A
receptors, and on the storage capacity of platelets (DaPrada et al. 1988). Therefore, the
intrafamilial correlation observed for whole blood 5-HT could result from the cumulative effect of
genetic factors that underlie each of these parameters.
Conclusion
The present findings show for the first time the presence of lower whole blood 5-HT
concentration, decreased platelet 5-HTT Bmax, and higher platelet IP3 content in the
unaffected parents of OCD patients, that could represent endophenotypes in this disorder.
Whether these serotonergic disturbances represent true biological markers of the genetic
susceptibility to OCD awaits replication in others samples. These abnormalities might lead to
the identification of individuals at risk for OCD, and, consequently, increase the power of
genetic analyses by identifying all the members of the pedigree carrying vulnerability factors.
By improving the phenotypic characterization of patients and unaffected relatives, these results
may contribute to the identification of more homogeneous subgroups and yield insights into the
neurobiological mechanisms involved in OCD.
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Table 1. Clinical and demographic characteristics of OCD probands and their unaffected parents
Probands
(n=48)
Unaffected relatives
(n=65)
Male/female 33/15 29/36
Age at interview (years)a 18.7 + 9.9 48.9 + 9.8
Age at onset of OCD (years) a 11.3 + 11.6 —
N° of drug-free/treated patients at inclusion 33/15 65/0
Y-BOCS total score
drug-free patients a 27.1 ± 5.7 —
treated patients a 20.3 ± 6.4 —
Y-BOCS checklist – main categories
Obsessions (%)
aggressive 68 —
contamination 68 —
sexual 24 —
hoarding 37 —
religious 50 —
symmetric/ordering 63 —
somatic 52 —
Compulsions (%)
washing 76 —
checking 81 —
repeating 73 —
counting 42 —
ordering 68 —
hoarding 30 —
a mean ± SD. Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
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Table 2. Effect of the 5-HTTLPR and intron 2VNTR polymorphisms of the 5-HTT gene on whole blood 5-
HT level and Kd or Bmax of 5-HTT (measured with [3H]-paroxetine and [3H]-imipramine) in a sample of
OCD probands (n = 48), their unaffected parents (n = 65), and controls (n = 113). Data represent means
± SD. Data were analyzed with non parametric analysis of variance (Kruskall-Wallis test); no significant
effect of the two polymorphisms was observed on any of the biochemical parameters studied.
5-HTTLPR Intron 2 VNTR
S/S S/L L/L 9/(10+12) 10/10 10/12 12/12
Controls (n=12) (n=63) (n=16) (n=2) (n=11) (n=44) (n=34)
5-HT (mM) 0.51 ± 0.17 0.49 ± 0.18 0.54 ± 0.15 0.39 ±0.01 0.48 ± 0.17 0.50± 0.18 0.52 ± 0.17
[3H]-paroxetine
Kd (nM) 0.16 ± 0.03 0.16 ± 0.03 0.15 ± 0.03 0.18 ± 0.03 0.16 ± 0.03 0.16 ± 0.03 0.17 ± 0.03
Bmax
(pmol/mg prot)
0.87 ± 0.13 0.85 ± 0.15 0.81 ± 0.16 0.81 ± 0.13 0.93 ± 0.15 0.84 ± 0.15 0.83 ± 0.15
[3H]-imipramine
Kd (nM) 1.27 ± 0.05 1.26 ± 0.05 1.26 ± 0.06 1.28 ± 0.07 1.27 ± 0.05 1.26 ± 0.05 1.26 ± 0.06
Bmax
(pmol/mg prot)
1.61 ± 0.14 1.62 ± 0.14 1.65 ± 0.12 1.84 ± 0.31 1.64 ± 0.13 1.62 ± 0.24 1.62 ± 0.21
Probands (n=4) (n=26) (n=15) (n=1) (n=5) (n=18) (n=24)
5-HT (mM) 0.49 ± 0.47 0.37 ± 0.29 0.33 ± 0.23 0.38 0.28 ± 0.33 0.42 ± 0.28 0.32 ± 0.26
[3H]-paroxetine
Kd (nM) 0.20 ± 0.17 0.14 ± 0.06 0.12 ± 0.05 0.13 0.14 ± 0.02 0.12 ± 0.07 0.13 ± 0.07
Bmax
(pmol/mg prot)
0.69 ± 0.15 0.59 ± 0.19 0.59 ± 0.23 0.62 0.52 ± 0.19 0.62 ± 0.22 0.58 ± 0.19
[3H]-imipramine
Kd (nM) 0.96 ± 0.13 1.13 ± 0.25 1.10 ± 0.26 1.14 1.23 ± 0.08 1.12 ± 0.24 1.08 ± 0.27
Bmax
(pmol/mg prot)
1.47 ± 0.24 1.46 ± 0.27 1.36 ± 0.26 1.36 1.49 ± 0.21 1.38 ± 0.28 1.44 ± 0.27
Relatives (n=12) (n=29) (n=24) (n=3) (n=6) (n=27) (n=29)
5-HT (µM) 0.33 ± 0.19 0.40 ± 0.20 0.38 ±0.22 0.29 ± 0.07 0.35 ± 0.16 0.38 ± 0.22 0.39 ± 0.21
[3H]-paroxetine
Kd (nM) 0.18 ± 0.05 0.16 ± 0.05 0.16 ± 0.05 0.17 ± 0.08 0.16 ± 0.03 0.17 ± 0.05 0.15 ± 0.05
Bmax
(pmol/mg prot)
0.65 ± 0.06 0.65 ± 0.04) 0.66 ± 0.05 0.65 ± 0.08 0.65 ± 0.03 0.66 ± 0.05 0.66 ± 0.05
[3H]-imipramine
Kd (nM) 1.25 ± 0.10 1.20 ± 0.04 1.20 ±0.06 1.19 ± 0.06 1.17 ± 0.03 1.21 ± 0.04 1.22 ± 0.09
Bmax
(pmol/mg prot)
1.20 ± 0.51 1.28 ± 0.39 1.15 ± 0.49 0.72 ± 0.58 0.82 ± 0.44 0.70 ± 0.45 0.68 ± 0.45
H
al author m
anuscript    inserm
-00109585, version 1
Delorme et al. 17
Figure 1. Whole blood 5-HT content, platelet 5-HT transporter binding sites (Bmax) and affinity (Kd)
measured with [3H]-imipramine and [3H]-paroxetine, platelet 5-HT2A receptor binding sites (Bmax) and
affinity (Kd) measured with [125I]-LSD, and platelet IP3 content in OCD patients (all, n=48; drug-free,
n=33; treated, n=15), unaffected parents (n=65), and their respective sex- and age-matched controls.
Data represent distribution and mean of each parameter. * p<0.05, **p<0.01, ***p<0.001, Mann-Whitney
U test.
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